[Recent progress in the medical treatment of rheumatoid arthritis].
Takeuchi
Tsutomu
T
tsutake@saitama-med.ac.jp
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005938:Glucocorticoids; D006801:Humans; D000069285:Infliximab; D010597:Pharmacogenetics; D018570:Risk Assessment; D016559:Tacrolimus / Q000008:administration & dosage
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D000069285:Infliximab; D016559:Tacrolimus